Trial Profile

An Open Label Study to Evaluate Safety and Tolerability of StroMel in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous adipose derived stromal vascular fraction therapeutic-Akan-Biosciences (Primary)
Indications Osteoarthritis
Focus Adverse reactions
Sponsors Akan Biosciences

Most Recent Events

29 Jan 2025 Planned End Date changed from 31 Dec 2022 to 31 Aug 2027.
29 Jan 2025 Planned primary completion date changed from 31 Dec 2022 to 31 Aug 2027.
29 Jan 2025 Planned initiation date changed from 22 Aug 2022 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com